Cagrilintide \u2013 d\u00e1vkovac\u00ed pero 10mg\/2ml (Long-Acting Amylin Analogue)<\/p>\n
Cagrilintide p\u0159edstavuje nejnov\u011bj\u0161\u00ed generaci syntetick\u00fdch peptidov\u00fdch analog\u016f p\u0159irozen\u00e9ho hormonu amylinu, kter\u00fd je ko-sekretov\u00e1n spole\u010dn\u011b s inzulinem beta-bu\u0148kami pankreatu v reakci na p\u0159\u00edjem potravy. Na rozd\u00edl od p\u0159irozen\u00e9ho amylinu je Cagrilintide chemicky modifikov\u00e1n (obsahuje mastnou kyselinu nav\u00e1zanou na \u0159et\u011bzec), co\u017e v\u00fdrazn\u011b prodlu\u017euje jeho biologick\u00fd polo\u010das rozpadu v organismu. V modern\u00edm biomedic\u00ednsk\u00e9m v\u00fdzkumu obezity a metabolick\u00e9ho syndromu je tato molekula pova\u017eov\u00e1na za pr\u016flomovou. Je toti\u017e zkoum\u00e1na pro sv\u016fj unik\u00e1tn\u00ed centralizovan\u00fd mechanismus kontroly t\u011blesn\u00e9 hmotnosti, kter\u00fd p\u016fsob\u00ed nez\u00e1visle na popul\u00e1rn\u00edch inkretinov\u00fdch drah\u00e1ch (jako jsou GLP-1 \u010di GIP), d\u00edky \u010demu\u017e nab\u00edz\u00ed zcela nov\u00fd pohled na \u0159e\u0161en\u00ed metabolick\u00fdch dysfunkc\u00ed.<\/p>\n
D\u00e1vkovac\u00ed pero obsahuje 10 mg vysoce \u010dist\u00e9 \u00fa\u010dinn\u00e9 l\u00e1tky ve 2 ml roztoku, co\u017e p\u0159edstavuje koncentraci p\u0159esn\u011b 5 mg\/ml. P\u0159epo\u010det pro p\u0159esn\u00e9 d\u00e1vkov\u00e1n\u00ed v r\u00e1mci v\u00fdzkumn\u00fdch protokol\u016f:<\/p>\n
1 ml = 100 jednotek (UI) = 100 kliknut\u00ed<\/p>\n
0,5 ml (jedno pln\u00e9 oto\u010den\u00ed mechanismu) = 50 kliknut\u00ed<\/p>\n
P\u0159\u00edklady d\u00e1vkov\u00e1n\u00ed pro v\u00fdzkumn\u00e9 \u00fa\u010dely:<\/p>\n
1 kliknut\u00ed = 0,05 mg (50 mcg) \u00fa\u010dinn\u00e9 l\u00e1tky<\/p>\n
2 kliknut\u00ed = 0,10 mg (100 mcg) \u00fa\u010dinn\u00e9 l\u00e1tky<\/p>\n
4 kliknut\u00ed = 0,20 mg (200 mcg) \u00fa\u010dinn\u00e9 l\u00e1tky<\/p>\n
10 kliknut\u00ed (0,1 ml) = 0,50 mg (500 mcg) \u00fa\u010dinn\u00e9 l\u00e1tky<\/p>\n
20 kliknut\u00ed (0,2 ml) = 1,00 mg (1000 mcg) \u00fa\u010dinn\u00e9 l\u00e1tky<\/p>\n
Tento mechanick\u00fd syst\u00e9m zaru\u010duje absolutn\u00ed p\u0159esnost, opakovatelnost a flexibilitu p\u0159i nastavov\u00e1n\u00ed mikrod\u00e1vek podle pot\u0159eb konkr\u00e9tn\u00edho laboratorn\u00edho protokolu bez nutnosti slo\u017eit\u00e9ho ru\u010dn\u00edho \u0159ed\u011bn\u00ed lyofilizovan\u00fdch ampulek.<\/p>\n
\u00da\u010dinky zkouman\u00e9 v\u00fdzkumem
\nZ\u00e1kladn\u00edm pil\u00ed\u0159em v\u00fdzkumu Cagrilintidu je jeho siln\u00e1 odezva v centr\u00e1ln\u00edm nervov\u00e9m syst\u00e9mu. L\u00e1tka p\u016fsob\u00ed jako neselektivn\u00ed agonista receptor\u016f pro amylin (AMY1 a\u017e AMY3) a kalcitonin. Tyto receptory jsou lokalizov\u00e1ny v oblastech mozku odpov\u011bdn\u00fdch za homeost\u00e1zu energie (zejm\u00e9na v area postrema a nucleus tractus solitarii). Aktivace t\u00e9to sign\u00e1ln\u00ed dr\u00e1hy vede k v\u00fdrazn\u00e9mu zpomalen\u00ed vyprazd\u0148ov\u00e1n\u00ed \u017ealudku a vysl\u00e1n\u00ed siln\u00e9ho neurogenn\u00edho sign\u00e1lu sytosti.<\/p>\n
V\u00fdzkumn\u00e1 data in vivo nazna\u010duj\u00ed, \u017ee Cagrilintide dok\u00e1\u017ee vyvolat v\u00fdznamn\u00fd \u00fabytek tukov\u00e9 tk\u00e1n\u011b. Mimo\u0159\u00e1dn\u011b zaj\u00edmavou oblast\u00ed prob\u00edhaj\u00edc\u00edho v\u00fdzkumu je jeho v\u00fdrazn\u00e1 synergie s agonisty GLP-1 receptor\u016f (jako je nap\u0159\u00edklad Semaglutid). Jeliko\u017e amylinov\u00e1 dr\u00e1ha kontroluje sytost jin\u00fdm neurologick\u00fdm mechanismem ne\u017e GLP-1, kombinovan\u00fd v\u00fdzkum t\u011bchto dvou drah sou\u010dasn\u011b vykazuje mnohem v\u00fdrazn\u011bj\u0161\u00ed sn\u00ed\u017een\u00ed p\u0159\u00edjmu kalori\u00ed a metabolickou optimalizaci ne\u017e ka\u017ed\u00e1 l\u00e1tka samostatn\u011b. Sou\u010dasn\u011b je sledov\u00e1n jeho vliv na potla\u010den\u00ed sekrece glukagonu a zlep\u0161en\u00ed celkov\u00e9 inzulinov\u00e9 senzitivity bun\u011bk.<\/p>\n
V\u011bdeck\u00fd kontext a zdroje
\nCagrilintide byl vyvinut p\u0159edn\u00edmi biomedic\u00ednsk\u00fdmi laborato\u0159emi a \u00fasp\u011b\u0161n\u011b pro\u0161el klinick\u00fdmi studiemi f\u00e1ze I a II, kter\u00e9 potvrdily jeho vysokou \u00fa\u010dinnost a p\u0159\u00edzniv\u00fd bezpe\u010dnostn\u00ed profil. Odborn\u00e9 publikace v respektovan\u00fdch l\u00e9ka\u0159sk\u00fdch \u010dasopisech, v\u010detn\u011b The Lancet, podrobn\u011b popisuj\u00ed jeho farmakokinetiku, stabilitu a na d\u00e1vce z\u00e1visl\u00fd vliv na redukci t\u011blesn\u00e9 hmotnosti u zkouman\u00fdch subjekt\u016f. Tyto pr\u00e1ce jsou pln\u011b dostupn\u00e9 v mezin\u00e1rodn\u00ed datab\u00e1zi PubMed.<\/p>\n
P\u0159esn\u00e1 data z prob\u00edhaj\u00edc\u00edch klinick\u00fdch projekt\u016f zam\u011b\u0159en\u00fdch na dlouhodobou kombinovanou terapii analog\u016f amylinu a inkretinov\u00fdch mimetik jsou shroma\u017e\u010fov\u00e1na v mezin\u00e1rodn\u00edm registru ClinicalTrials.gov, kde tato molekula p\u0159edstavuje kl\u00ed\u010dov\u00fd model pro v\u00fdvoj budouc\u00edch pokro\u010dil\u00fdch terapi\u00ed obezity a diabetu 2. typu.<\/p>\n
D\u00e1vkovac\u00ed pero od Royal Peptides poskytuje modern\u00ed, bezpe\u010dn\u00e9 a vysoce steriln\u00ed \u0159e\u0161en\u00ed pro manipulaci s touto pokro\u010dilou molekulou v kontrolovan\u00fdch laboratorn\u00edch podm\u00ednk\u00e1ch.<\/p>\n
Produkt je ur\u010den v\u00fdhradn\u011b pro v\u011bdeck\u00e9 a v\u00fdzkumn\u00e9 \u00fa\u010dely. Nen\u00ed ur\u010den k p\u0159\u00edm\u00e9 konzumaci.<\/p>\n","protected":false},"excerpt":{"rendered":"
D\u00e1vkovac\u00ed pero Royal Peptides \u2013 Cagrilintide 10mg\/2ml<\/p>\n
Modern\u00ed a praktick\u00e9 d\u00e1vkovac\u00ed pero navr\u017een\u00e9 pro p\u0159esn\u00e9 a pohodln\u00e9 d\u00e1vkov\u00e1n\u00ed v\u00fdzkumn\u00fdch slou\u010denin. Elegantn\u00ed design, kompaktn\u00ed proveden\u00ed a jednoduch\u00e9 ovl\u00e1d\u00e1n\u00ed umo\u017e\u0148uj\u00ed efektivn\u00ed manipulaci v laboratorn\u00edm prost\u0159ed\u00ed.<\/p>\n
Cagrilintide je inovativn\u00ed experiment\u00e1ln\u00ed peptidov\u00e1 slou\u010denina, kter\u00e1 p\u016fsob\u00ed jako dlouhodob\u011b \u00fa\u010dinn\u00fd agonista amylinov\u00fdch receptor\u016f (AMY). Je p\u0159edm\u011btem intenzivn\u00edho v\u011bdeck\u00e9ho v\u00fdzkumu v oblasti regulace homeost\u00e1zy gluk\u00f3zy, neurogenn\u00edho potla\u010den\u00ed chuti k j\u00eddlu a \u0159\u00edzen\u00ed t\u011blesn\u00e9 hmotnosti prost\u0159ednictv\u00edm aktivace centr\u00e1ln\u00edch mechanism\u016f sytosti.<\/p>\n
Jehly nejsou sou\u010d\u00e1st\u00ed balen\u00ed a nejsou ani v na\u0161\u00ed nab\u00eddce.<\/p>\n
Produkt je ur\u010den v\u00fdhradn\u011b pro v\u011bdeck\u00e9 a v\u00fdzkumn\u00e9 \u00fa\u010dely.<\/p>\n","protected":false},"featured_media":7678,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[160,156,301],"product_tag":[],"class_list":["post-7679","product","type-product","status-publish","has-post-thumbnail","product_cat-hormonalni-rovnovaha","product_cat-hubnuti","product_cat-doplnky","first","instock","purchasable","product-type-simple"],"yoast_head":"\n